Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THIN Levell 2 ASK!!! RUNNER IS HERE!!!
IMO
This could run to $10.00 EASY!
IMO
Breakout coming.. Levell 2 thin!!
IMO
More volume coming.. Here we go!!!! Weeee!!!!!!!!!
IJMO
.44 hitting..
IMO
.44 up ~
BOOOOM!!!!!!!!!!!
IMO
Up .37
IMO
THINKING LIKE 6 - 7 MIL
That's an ancient float, current significantly higher...
Make money first. Be right second
Financials are brutal.. $7m loss thru first 9 months. Up from $4m loss last year. No company can stay in business putting up them yuck numbers.
Look around, it's a low float PnD.
You guys need to slow your roll and quit slapping the ask.
There could be 20 million of these puppies coming out Northland Capital was to IPO it on Nasdaq at 4.50 to 5.50 and Nuo Ther pulled it sighting market conditions, now Northland is the MM for it, so whats the deal with that shit, instead of IPO for 2.1 million now these are out here for a nickel?
Its ok if there are xyz amount of shares and they can be collected at .05 but slapping the ask is not to good IMHO. But you can do as you please, anyone feel like calling Northland at their NY office and checking the OS numbers?
I read somewhere that Eli Lilly got their proprietary shit for their main money maker, probably why they are doing 160K a quarter not instead of millions. Maybe after they pulled the IPO they sold off the goods as the bankruptcy judge said that was what needed to be done. Its a ball of string and knots, maybe they still have whatever bankrupted them there is a board on here NUOT where they were listed before bankruptcy, haven't had time as I said in spare time I been jumping in one rabbit hole after another with this chit.
I hate talking on the phone? Deerfield was supposed to get a ton after the bankruptcy as well as warrants. So many filings and holes to crawl down into all the while watching this go on on this board and on the chart. I am not being a now it all just throwing a heads up out there.
I already have quite a few and would like some more but people keep coming by slapping the ask and bringing attention to them. FWIW better to accumulate at .05 I got 50K free ones from buying at .05 and selling at .15+ but its been slow going with ask slaps but then again I wouldn't have free ones if there weren't but .25 going to bring eyes on this thing, who knows and how many are there exactly and when do Deerfields warrants come through with 10's of millions more? It could be Ferrari money or it could just be Lincoln Navigator money I already have one nothing special just like this stock could be?
Anyway just figured I would throw that out there, you could really take one in the ass bum rushing in to it. Figured I would be neighborly and try and maybe save ya some headache. As I said they probably do not have the money maker shit anymore Eli Lilly just may have that, oh well I am rambling now off to look some more in the rats nest that is the paperwork for this thing. Peace Out
. (OTCPK:AURX) is looking for acquisitions. Nuo Therapeutics may also use a portion of the net proceeds for the acquisition of, or investment in, technologies, solutions or businesses
Tic Tic Tic
TOCK
PHARMA GAINS = Ferrari money
OTCQX
DOLLARS
Looking good here. This one will be back over $1 sooner than later. Hearing good things
$AURX .. low floater ..active ask slaps thought out the day .. looking for strong uptrend next week .. !
First time being in at the beginning! This is gonna be fun. Soon as people see what the potential here is, it's off to the races. $AURX
Charles E. Sheedy, CFA
Senior Vice President
Portfolio Management
Investment Committee Member
Charles E. Sheedy is a Senior Vice President at Fayez Sarofim & Co. and a member of the Firm’s Investment Committee. He is co-manager of the mutual funds that Fayez Sarofim & Co. manages for The Dreyfus Corporation and serves on the board of Sarofim Trust Co. Additionally, he is a portfolio manager for a variety of institutional and high net worth clients. Mr. Sheedy joined the Firm 1971 as an Associate. Over the years, areas of responsibility have included retail, electrical equipment, consumer staples, basic industries and health care.
Mr. Sheedy received a M.B.A. from Harvard Business School in 1971 and graduated cum laude from the University of Notre Dame in 1969.
Mr. Sheedy is a member of the Notre Dame Arts & Letters Advisory Counsel.
https://www.sarofim.com/leadership.html
was just $2 WHY DO INSIDERS OWN 72%?
why did Boyalife Investment Fund I, Inc just purchase 3.1 million shares at .22
why did SHEEDY CHARLES E just purchase 5.2 million shares at 22 cents (that's over $1.1 million folks)
http://www.nuot.com/
http://aurixsystem.com/
Description
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies for wound care. The Company's flagship product, Aurix is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds.
Contact Details
207A Perry Parkway
Suite 1
Gaithersburg, MD 20877
www.nuot.com
(240) 499-2680
djorden@nuot.com
https://www.otcmarkets.com/stock/AURX/research
Feb 14, 2018
Quantitative Equity Report
Morningstar
AURX Security Details
Share Structure
Market Cap 2,045,016 02/13/2018
Authorized Shares 31,500,000 01/31/2018
Outstanding Shares 22,722,400 01/31/2018
Restricted Not Available
Unrestricted Not Available
Held at DTC Not Available
Float 1,816,385 11/22/2016
Par Value No Par Value
Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 825 03/28/2017
What is Aurix®?
Skin ulcers and wounds that don’t heal can have a significant impact on a patient’s quality of life and present a treatment challenge for healthcare providers. Aurix is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms in order to jumpstart the healing process from deep within the wound bed.
http://aurixsystem.com/
The secret ingredient to healing? Your patient.
Aurix® is a breakthrough wound care solution that starts and ends with the patient.
Aurix. Heal on.
About Aurix™
Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.
Broaden Your Reach
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).
Aurix can be used successfully on patients with:
Tunneling
Sinus tracts
Bone and tendon exposure
Hardware exposure
Flexibility for Patients and Providers
Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.
About Us
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.
Vision for Change
Through bold leadership, better clinical solutions, and products that add true value to a patient’s health, we aim to offer more effective and efficient therapies for healing.
Advancing Wound Care
Nuo Therapeutics’ flagship product, Aurix™, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. It is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types. Read more about the Aurix System.
Management
Chief Science Officer
David E. Jorden, CPA,
Chief Executive Officer & Chief Financial Officer
Peter A. Clausen, Ph.D., Chief Science Officer
Dr. Clausen joined Nuo Therapeutics in September 2008 and has more than 20 years of experience in the biotechnology industry. Prior to joining Nuo Therapeutics, Dr. Clausen was a founding member and Vice President of Research and Development at Marligen Bioscience, where he developed and commercialized innovative genomic and protein analysis products for the life sciences market. Dr. Clausen was the Manager of New Purification Technologies at Life Technologies and the Invitrogen Corporation. He also has significant experience within the commercial biotechnology industry developing peptide and small molecule therapeutics for application in the areas of inflammatory mediated disease and stem cell transplantation. He completed his post-doctoral training at the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned his PhD in Biochemistry from Rush University in Chicago and a Bachelor of Science degree in Biochemistry from Beloit College.
Board of Directors
David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer
Paul D. Mintz, MD
C. Eric Winzer
Lawrence S. Atinsky
Scott M. Pittman
David E. Jorden, CPA, Chief Executive Officer & Chief Financial Officer
David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
154
|
Created
|
02/13/18
|
Type
|
Free
|
Moderators |
Nuo Therapeutics, Inc. is a biomedical company that pioneers leading-edge biodynamic therapies within the emerging opportunities of a changing healthcare landscape.
Through bold leadership, better clinical solutions, and products that add true value to a patient’s health, we aim to offer more effective and efficient therapies for healing.
Nuo Therapeutics’ flagship product, Aurix™, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. It is the only therapy of its kind that is FDA-cleared for use on ulcers and wounds of all types.
Dr. Clausen joined Nuo Therapeutics in September 2008 and has more than 20 years of experience in the biotechnology industry. Prior to joining Nuo Therapeutics, Dr. Clausen was a founding member and Vice President of Research and Development at Marligen Bioscience, where he developed and commercialized innovative genomic and protein analysis products for the life sciences market. Dr. Clausen was the Manager of New Purification Technologies at Life Technologies and the Invitrogen Corporation. He also has significant experience within the commercial biotechnology industry developing peptide and small molecule therapeutics for application in the areas of inflammatory mediated disease and stem cell transplantation. He completed his post-doctoral training at the Laboratory of Molecular Oncology at the National Cancer Institute where his research efforts focused in the areas of oncology, hematopoiesis, and gene therapy. Dr. Clausen earned his PhD in Biochemistry from Rush University in Chicago and a Bachelor of Science degree in Biochemistry from Beloit College.
David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.
Board of Directors
David E. Jorden has been Chief Executive Officer and Chief Financial Officer of the Company effective July 1, 2016 after serving as Acting CEO since January 8, 2016 and Acting CFO since May 2015. Mr. Jorden also serves as Acting Secretary of the Company, and has served on the Board of Directors since October 2008 and was Executive Chairman from February 2012 to May 2015. From 2003 to 2008, he was with Morgan Stanley’s Private Wealth Management group where he was responsible for equity portfolio management for high net worth individuals. Prior to Morgan Stanley, Mr. Jorden served as CFO for Genometrix, Inc., a private genomics/life sciences company focused on high-throughput microarray applications. Mr. Jorden was previously a principal with Fayez Sarofim & Co. Mr. Jorden has a MBA from Northwestern University’s Kellogg School and a B.B.A. from University of Texas at Austin. He holds both Certified Financial Analyst and Certified Public Accountant designations. Mr.Jorden serves on the board of Opexa Therapeutics, Inc. (Nasdaq: OPXA) where he has held the position of Acting Chief Financial Officer since August 2012. He is also on the board of a private companies, PLx Pharma, Inc., a specialty pharmaceutical company developing GI safer NSAIDs (nonsteroidal anti-inflammatory drugs). Mr. Jorden brings his experience and expertise in the areas of capital raising, investor relations, financial management and analysis, and business strategy to the Board and the Company.
Paul D. Mintz, MD was elected to the Nuo Therapeutics, Inc. Board of Directors, effective April 7, 2017. Dr. Mintz is currently the Senior Vice President and Chief Medical Officer of Verax Biomedical. Prior to joining Verax Biomedical in early 2016, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration. Prior to that, for more than 30 years, Dr. Mintz was a member of the faculty of the University of Virginia School of Medicine, where he was a tenured Professor of Pathology and Internal Medicine. He also served as Vice-Chair of Pathology and Chief of the Division of Clinical Pathology, and as Medical Director of the Clinical Laboratories and Transfusion Medicine Services at the University of Virginia Health System. In addition, Dr. Mintz served as Co-Medical Director of Virginia Blood Services. Dr. Mintz is a former President of the American Association of Blood Banks (AABB), served on the AABB’s Board of Directors for nine years, and was a member of and chaired numerous AABB committees. Dr. Mintz is a recipient of the AABB’s John Elliott Memorial Award. He has also served as a member of the Board of Trustees of the National Blood Foundation. Dr. Mintz is the recipient of a Transfusion Medicine Academic Award from the National Heart, Lung and Blood Institute, and was an inaugural inductee into the National Blood Foundation Hall of Fame. He also served as a member of the Medicare Coverage Advisory Committee of the Centers for Medicare and Medicaid Services (CMS). Dr. Mintz is author or co-author of more than 100 articles and editorials spanning clinical practice, blood safety and the evaluation of new transfusion medicine technologies, and has designed and served as principal investigator for numerous clinical trials. He is the sole editor of all three editions of Transfusion Therapy: Clinical Principles and Practice (AABB Press) and has served on several journal editorial boards. Dr. Mintz earned his BA in Philosophy from the University of Rochester and received his MD with honors from the University of Rochester School of Medicine. Dr. Mintz brings considerable knowledge of platelet biology and transfusion medicine, along with senior regulatory and reimbursement experience to Nuo Therapeutics, and will be enormously valuable as the company strives to advance the Aurix System toward broader commercialization in the large and growing chronic wound care market.
C. Eric Winzer has served as Director since January 30, 2009. Mr. Winzer has over 30 years of experience in addressing diverse financial issues including raising capital, financial reporting, investor relations, banking, taxation, mergers and acquisitions, financial planning and analysis, and accounting operations. Mr. Winzer has been the Chief Financial Officer at Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company, since May 2015. From June 2009 to April 2015 Mr. Winzer served as the Principal Accounting Officer, Senior Vice President of Finance, and Chief Financial Officer for OpGen Inc. (OPGN), a precision medicine company that went public in May 2015. Before his tenure with OpGen Inc., Mr. Winzer held multiple executive positions at Avalon Pharmaceuticals, Inc. (AVRX), a NASDAQ listed biotechnology company, including serving as its Chief Financial Officer and Executive Vice President, Principal Accounting Officer, and Secretary. Before joining Avalon Pharmaceuticals, Mr. Winzer held numerous senior financial positions over twenty years at Life Technologies Corporation (LIFE) (now part of Thermo Fisher Scientific (TMO)) and its predecessor companies, Invitrogen (IVGN) and Life Technologies, Inc. (LTEK). From 1980 to 1986, Mr. Winzer held various financial positions at Genex Corporation. Mr. Winzer has been an Independent Director at Nuo Therapeutics (f/k/a Cytomedix, Inc.) since January 30, 2009. Mr. Winzer holds a B.A. in Economics and Business Administration from Western Maryland College (now, McDaniel College) and an M.B.A. from Mount Saint Mary's University. Mr. Winzer was chosen to serve as a director of the Company in part because of his executive experience in the life sciences industry and his substantial financial knowledge and expertise.
Lawrence S. Atinsky has served as a director since May 5, 2016. Mr. Atinsky is a Partner at Deerfield Management Company, LP (“Deerfield Management”), a healthcare investment firm focused on advancing healthcare through investment, information and philanthropy. He primarily focuses on the firm’s structured transactions and private equity investments. Prior to joining Deerfield Management, Mr. Atinsky was a partner of Ascent Biomedical Ventures, a healthcare focused private equity firm investing in early-stage biomedical and medical device companies. He has over 18 years of experience investing in healthcare companies and currently serves on the Board of FluoroPharma Medical, Inc. Mr. Atinsky earned a J.D. from New York University School of Law and B.A. degrees in Political Science and Philosophy from the University of Wisconsin-Madison, cum laude. Deerfield Management’s affiliates are currently the sole holders of our Series A Preferred Stock and Mr. Atinsky serves as their designee to our Board of Directors under the Certificate of Designations for our Series A Preferred Stock.
Scott M. Pittman has served as a director since May 5, 2016. Mr. Pittman has over 30 years in Hospital Executive management. He is a Chief Operating & Business Development Officer for Buchanan General Hospital, a Registered Representative with Calton & Associates, and a Principal of Hospital CEO Associates. He has served as CEO Florida Hospital Zephyrhills, FL, in senior executive positions with Adventist Health Systems, and in various hospital executive positions in southern West Virginia. Mr. Pittman has developed several multimillion dollar hospital and program service expansions, and healthcare entity acquisitions and mergers, and has served on numerous state and regional health planning organizations. He is a Magna cum Laude graduate of Southwestern Adventist University with B.S. & B.A. Degrees in Business and Religion, and a Masters of Hospital Administration from Medical College of Virginia. Mr. Pittman was chosen to serve as a director of the Company in part because of his extensive experience as a hospital executive.
Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).
Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.
Aurix™ is a biodynamic hematogel that harnesses a patient’s innate healing mechanisms to jumpstart the natural healing process.
Aurix is the first platelet and plasma therapy system to be cleared by the FDA for the management of ulcers and wounds of all types (DFU, pressure, VLU, etc.) and all severities (partial thickness, full thickness, and complex wounds).
Aurix is effective at all stages of wound care for non-healing wounds, allowing providers more treatment flexibility across a broader range of patients.
For more information about our company or our products, please contact or fill out the form on www.nuot.com/contact/
Corporate Offices
207A Perry Parkway, Suite 1
Gaithersburg, MD 20877
Nashville Office
618 Church St., Suite 305
Nashville, TN 37219
Phone
1.866.298.6633
Fax
1.240.499.2690
Email
info@nuot.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |